血液生物标志物对心脏骤停后患者神经预后的准确性:系统评价与荟萃分析
该研究系统检索PubMed和Embase至2019年3月,纳入42项研究共4806例成人心脏骤停后患者,采用QUADAS-2评估偏倚风险及贝叶斯双变量随机效应模型合成预后数据。NSE预测神经预后的汇总敏感性为0.56(95%CrI 0.47-0.65),汇总特异性为0.99(95%CrI 0.98-1.00);S-100B的汇总敏感性为0.63(95%CrI 0.46-0.78),汇总特异性为0.97(95%CrI 0.92-1.00)。NSE异质性I²为22.4%,S-100B异质性I²为16.1%,均较低,发表偏倚不显著。亚组分析显示两种标志物在不同人群、不同测量时机和不同结局评估时机下均保持高特异性。作者认为两者预后性能相当,均可整合入多模式神经预后评估算法,并应建立机构特异性截断值。
要点
- 成人心脏骤停后神经预后预测中,NSE汇总敏感性0.56(95%CrI 0.47-0.65)、特异性0.99(95%CrI 0.98-1.00)。
- S-100B汇总敏感性0.63(95%CrI 0.46-0.78)、特异性0.97(95%CrI 0.92-1.00),与NSE预后性能相当。
- NSE异质性I²为22.4%,S-100B异质性I²为16.1%,均较低,发表偏倚不显著。
- 亚组分析显示两种标志物在不同人群(院外心脏骤停与否、是否接受目标温度管理)、不同测量时机和不同结局评估时机下均保持高特异性。
- 作者认为两种标志物均可整合入心脏骤停后患者的多模式神经预后评估算法,并应建立机构特异性截断值。
适用人群与场景
- 成人心脏骤停后患者,用于预测神经预后。
- 亚组分析涵盖院外心脏骤停与非院外心脏骤停患者、接受与未接受目标温度管理的患者。
研究设计与关键结果
- 系统评价与荟萃分析,纳入42项研究共4806例成人心脏骤停后患者,检索PubMed和Embase自建库至2019年3月。
- NSE预测神经预后汇总敏感性0.56(95%CrI 0.47-0.65),汇总特异性0.99(95%CrI 0.98-1.00)。
- S-100B汇总敏感性0.63(95%CrI 0.46-0.78),汇总特异性0.97(95%CrI 0.92-1.00)。
- NSE异质性I²为22.4%,S-100B异质性I²为16.1%,均较低;发表偏倚不显著。
- 亚组分析显示两种标志物在不同人群、不同测量时机和不同结局评估时机下均保持高特异性。
证据类型、等级与局限
- 证据类型:系统评价与荟萃分析,采用QUADAS-2评估偏倚风险,贝叶斯双变量随机效应模型合成数据,研究方案注册于PROSPERO(CRD42018084933)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为NSE与S-100B预后性能相当,两者均可整合入心脏骤停后患者的多模式神经预后评估算法。
- 作者认为应建立两种标志物的机构特异性截断值。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
AIM: To summarise and compare the prognostic accuracy of the blood biomarkers of brain injury, including NSE and S-100B, for neurological outcomes in adult post-cardiac arrest patients.
METHODS: We systematically searched PubMed and Embase databases from their inception to March 2019. We selected studies providing sufficient data of prognostic values of NSE or S-100B to predict neurological outcomes in adult post-cardiac arrest patients. We adopted QUADAS-2 to assess risk of bias and a Bayesian bivariate random-effects meta-analysis model to synthesise the prognostic data. The study protocol was registered with PROSPERO (CRD42018084933).
RESULTS: We included 42 studies involving 4806 patients in the meta-analysis. The NSE was associated with a pooled sensitivity of 0.56 (95% credible interval [CrI], 0.47-0.65) and pooled specificity of 0.99 (95% CrI, 0.98-1.00). The S-100B was associated with a pooled sensitivity of 0.63 (95% CrI, 0.46-0.78) and pooled specificity of 0.97 (95% CrI, 0.92-1.00). The heterogeneity for NSE (I2, 22.4%) and S-100B (I2, 16.1%) was low and publication bias was not significant. In subgroup analyses, both biomarkers were associated with high specificity across all subgroups with regard to different populations (i.e. whether patients were out-of-hospital cardiac arrest or whether patients received targeted temperature management), different timings of measurement, and different timings of outcome assessment.
CONCLUSIONS: The prognostic performance was comparable between NSE and S-100B. Both biomarkers may be integrated into a multimodal neuroprognostication algorithm for post-cardiac arrest patients and institution-specific cut-off points for both biomarkers should be established.
参考来源
- Wang CH, Chang WT, Su KI, et al. Neuroprognostic accuracy of blood biomarkers for post-cardiac arrest patients: A systematic review and meta-analysis. Resuscitation. 2020. PMID: 31978453. doi:10.1016/j.resuscitation.2020.01.006
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。